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Summary
Objectives: Pre-antiretroviral therapy (ART) HIV-related survival and timing of HIV identification
have not been reported from the Caribbean. Using Jamaican national surveillance data, we
estimated overall, AIDS-free, and AIDS survival, identified factors influencing HIV-related mor-
tality, and examined factors associated with late HIV/AIDS identification.
Methods: The Jamaican HIV/AIDS tracking system (HATS) national surveillance data included
timing of first positive HIV test, stage at identification, date of AIDS diagnosis, and death. We
estimated overall and AIDS-free survival by initial stage, using a proportional hazard model to
identify factors associated with worse survival, and logistic regression to examine factors related
to later case identification.
Results: Of 10 674 reported HIV cases, 48% were asymptomatic, 14% symptomatic, and 38% first
reported with AIDS. Five-year AIDS-free survival was 77% for asymptomatic persons and 63% for
symptomatic. Median survival after AIDS diagnosis was 1.02 years. Age, number of opportunistic
diseases, and initial stage were strongly associated with mortality. Older age, drug use, and sex
with a commercial sex worker were associated with later identification.
Conclusions: In the pre-ART era, over one-third of HIV-infected persons in Jamaica were first
identified with advanced disease. This highlights the need for earlier diagnosis as ART programs
roll out in the Caribbean.
# 2007 International Society for Infectious Diseases. Published by Elsevier Ltd. All rights
reserved.* Corresponding author. Tel.: +1 617 724 4636.
E-mail address: elosina@partners.org (E. Losina).
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An estimated 250 000 people are living with HIV in the
Caribbean, and more than 19 000 people died of AIDS in this
region in 2006 alone.1 Jamaica is the third largest Caribbean
island (estimated population 2 760 000) with a documented
HIV prevalence of 1.5%.2,3 The Jamaican Ministry of Health,
through its National HIV/STD Prevention and Control Pro-
gram, has carefully documented countrywide trends in the
HIV/AIDS epidemic, including incidence of AIDS cases, rate of
HIV infection, HIV prevalence, and mode of HIV transmis-
sion.4—6 While data from the early years of the epidemic in
Jamaica showed an AIDS case rate that doubled every two
years between 1987 and 1993,4 the yearly increase in AIDS
incidence has subsequently slowed, which has been attrib-
uted to the scale-up of the National HIV/STD Prevention and
Control Program.5 The HIV/AIDS tracking system (HATS)
national surveillance data are a rich resource for studying
HIV epidemic-related information. Though the HIV/AIDS epi-
demic in Jamaica has been well described, there are few data
documenting HIV-related survival, the prevalence of HIV
morbidities, and factors associated with worse survival and
later case identification.3—5,7
Understanding HIV-related survival during the pre-antire-
troviral therapy (ART) era is crucial for developing and eval-
uating the success of the growing ART program in Jamaica. As
access to ARTwas limited in Jamaica prior to 2005, there were
few persons in the HATS data on ART. We analyzed the HATS
database to assess: (1) survival in HIV-infected persons in
Jamaica and factors influencing HIV-related mortality, (2)
prevalence of HIV-related morbidities, and (3) factors asso-
ciated with later case identification. These data can provide
insight for planning and implementing effective prevention
and care interventions including ARTprograms in Jamaica and,
more widely, in the Caribbean region.
Methods
Data source and data elements
The Jamaican national HATS data collected from 1993 to 2005
were used for this analysis. HATS data collection was con-
ducted through provider-initiated reporting as well as
through active hospital surveillance using a standardized
instrument. The date and results of HIV tests, clinical data
including documentation of HIV-related morbidity, and dis-
ease stage (asymptomatic HIV, symptomatic HIV, AIDS, and
death) were captured. Standard case definitions for HIV
morbidities were used. The data also included information
on demographics including age, sex, and risk factors for HIV
infection. Risk factors included drug use (cocaine or injection
drug use), sex with a commercial sex worker, history of or
current sexually transmitted disease, and history of blood
transfusion. The HATS database team has several established
measures to maintain the confidentiality and security of the
data, including strictly confidential name-based reporting,
limited size of the surveillance team, restricted access to the
surveillance database, and a code-based version of the data-
base used for research purposes.
To adjust for secular trends in HIV-related survival, we
divided the surveillance data into three eras according to thedate of case identification (January 1, 1993 to December 31,
1996, January 1, 1997 to December 31, 2000, and January 1,
2001 to June 1, 2005). To ensure completeness of the data,
this analysis was restricted to persons who were diagnosed
after 1993. Persons with inconsistent data were excluded to
maximize completeness.
Statistical analysis
In the survival time analysis, we distinguished three types of
survival: overall survival for HIV-infected persons, AIDS-free
survival, and survival of persons living with AIDS (PLWA). To
estimate overall survival, the follow-up time for the analysis
was determined from the time of the first positive HIV test to
the date of death for those who died or to the end of the
follow-up period (June 1, 2005) for those who remained alive.
AIDS-free survival was estimated for those diagnosed at
earlier stages of disease (asymptomatic HIV and symptomatic
HIV) with follow-up time defined from the date of the first
positive HIV test to the date of AIDS diagnosis for those who
developed AIDS or to the end of the follow-up period for those
whose date of AIDS diagnosis was missing. We also estimated
survival of PLWA, defining follow-up time from the date of the
first diagnosis of AIDS to the date of death or the end of the
follow-up period for those who did not have a recorded date
of death.
We used the Kaplan—Meier method to estimate overall,
AIDS-free, and PLWA survival. We built proportional hazard
models to perform a multivariate analysis to identify factors
associated with worse survival. We also used logistic regres-
sion models to examine factors related to later HIV identi-
fication. For the purpose of this analysis, risk factors were
divided into six groups: (1) drug use (cocaine or injection drug
use), (2) sex with a commercial sex worker, (3) history of or
current sexually transmitted disease, (4) blood transfusion,
(5) pregnancy, and (6) other risks. All analyses were per-
formed using SAS 9.1 (SAS Institute, Cary, North Carolina,
USA); two-sided p-values <0.05 were used to define statis-
tical significance.
Results
Sample description
A total of 10 674 HIV-infected adults reported to the Jamai-
can national surveillance program between January 1, 1993
and June 1, 2005 met the inclusion criteria for the analysis
(Table 1). The majority of reported HIV cases (87%) were at
least 25 years of age, and 53% were male. Five thousand one
hundred fifty-four people (48%) were identified with asymp-
tomatic HIV, 1480 (14%) were identified with symptomatic
HIV, and 4040 (38%) were first reported with an AIDS diag-
nosis. Forty-eight percent of people had at least one defined
symptom complex or opportunistic disease throughout the
course of follow-up and 38% were observed to have two or
more symptom complexes during follow-up. The number of
people reported with HIV also increased over time, (1751,
3531, and 5392 cases of HIV reported over the three time
periods), with the proportion of reported cases with AIDS
greatest in the earliest time period (Table 2). The proportion
of patients reported earlier in the course of disease was
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Table 1 Characteristics of persons in the Jamaican HIV/AIDS tracking system (HATS) database: 1993—2005
N (%) Death (%) Crude hazard ratio
(95% CI)
Adjusted hazard ratio
(95% CI) a
Total 10 674 3368 (32) — —
Age at diagnosis (years)
18—24 1384 (13) 228 (16) 0.36 (0.31—0.41) 0.74 (0.64—0.86)
25—40 5752 (54) 1712 (30) 0.66 (0.62—0.71) 0.91 (0.84—0.97)
>40 3538 (33) 1428 (40) 1.00 1.00
Gender
Female 4973 (47) 1375 (28) 0.80 (0.75—0.86) 0.99 (0.92—1.06)
Male 5701 (53) 1993 (35) 1.00 1.00
Initial stage
Asymptomatic HIV 5154 (48) 710 (14) 0.16 (0.15—0.18) 0.32 (0.29—0.35)
Symptomatic HIV 1480 (14) 377 (25) 0.30 (0.27—0.33) 0.49 (0.44—0.55)
AIDS 4040 (38) 2281 (56) 1.00 1.00
Number of opportunistic diseases
0 5601 (52) 740 (13) 0.18 (0.17—0.20) 0.36 (0.32—0.40)
1 972 (9) 286 (29) 0.43 (0.38—0.49) 0.55 (0.48—0.62)
2 4101 (38) 2342 (57) 1.00 1.00
Date of HIV diagnosis
January 1, 1993—December 31, 1996 1751 (16) 763 (44) 0.90 (0.82—1.00) 0.82 (0.74—0.91)
January 1, 1997—December 31, 2000 3531 (33) 1237 (35) 0.86 (0.79—0.93) 0.96 (0.88—1.04)
January 1, 2001—June 1, 2005 5392 (51) 1368 (25) 1.00 1.00
Risk factors
Drug useb 554 (5) 222 (40) 1.58 (1.35—1.85) 1.07 (0.91—1.25)
Sex with CSW 1319 (12) 538 (41) 1.50 (1.33—1.69) 1.11 (0.98—1.26)
STD, past or current 3278 (31) 915 (28) 1.08 (0.97—1.20) 0.96 (0.87—1.07)
Blood transfusion history 440 (4) 142 (32) 1.23 (1.02—1.48) 0.94 (0.78—1.13)
Pregnancy 217 (2) 11 (5) 0.26 (0.14—0.48) 0.56 (0.30—1.06)
Unknown 2592 (24) 905 (35) 1.69 (1.51—1.88) 1.63 (1.46—1.82)
Other 151 (1) 54 (36) 1.43 (1.08—1.89) 1.05 (0.79—1.39)
No risk factors 2056 (19) 540 (26) 1.00 1.00
CI, confidence interval; CSW, commercial sex worker; STD, sexually transmitted disease.
a Adjusted hazard ratios are adjusted for all other variables shown in the table.
b Drug use includes cocaine and injection drug use.greater in the more recent time periods (52% and 50%
reported with asymptomatic HIV in the second and third time
periods, respectively). The cumulative incidence of progres-
sion to AIDS over the 11.5 years was 24% (1616 AIDS cases/
6634 persons) or 5.7 cases/100 person-years (PY). Progres-
sion to AIDS was lower for those who presented with asymp-
tomatic HIV (5.0 cases/100 PY) compared to those who
presented with symptomatic HIV (8.0 cases/100 PY).
Survival
Three thousand three hundred sixty-eight HIV-infected per-
sons died during the follow-up period (a total of 38 120 PY),
yielding a mortality rate of 8.8 deaths/100 PY. Death rates
were higher with increasing age, later stage of presentation,
greater number of symptom complexes or opportunisticdiseases, and unknown risk factors (Table 1). Mortality rates
were significantly higher for those identified at a later stage of
HIV disease (23.3 deaths/100 PY for those with AIDS at identi-
fication, 5.6 deaths/100 PY for persons with symptomatic HIV
at the time of identification, and 3.3 deaths/100 PY for those
identified with asymptomatic HIV). Among persons presenting
with asymptomatic HIV, one- and five-year survival rates were
97% and 85%, compared to 91% and 72% for persons initially
presenting with symptomatic HIV and 56% and 40% for persons
initially presenting with AIDS. Median survival after an AIDS
diagnosis was 1.02 years (Figure 1).
We also estimated AIDS-free survival for persons initially
presenting at earlier stages, prior to development of AIDS.
One- and five-year AIDS-free survival for persons diagnosed
with asymptomatic HIV were 92% and 77%, compared to 81%
and 63% for persons diagnosed with symptomatic HIV.
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Table 2 Factors associated with late case identification in the Jamaican HIV/AIDS tracking system (HATS) database: 1993—2005
Late presentation
(%)
Crude odds ratio
(95% CI)
Adjusted odds ratio
(95% CI) a
Total 4040 (38) — —
Age at diagnosis (years)
18—24 274 (20) 0.24 (0.21—0.28) 0.28 (0.24—0.32)
25—40 1968 (34) 0.50 (0.46—0.54) 0.53 (0.48—0.57)
>40 1798 (51) 1.00 1.00
Gender
Female 1657 (33) 0.69 (0.64—0.75) 0.91 (0.83—0.99)
Male 2383 (42) 1.00 1.00
Date of HIV diagnosis
January 1, 1993—December 31, 1996 759 (43) 1.27 (1.13—1.41) 1.18 (1.05—1.33)
January 1, 1997—December 31, 2000 1249 (35) 0.91 (0.83—0.99) 0.91 (0.83—0.99)
January 1, 2001—June 1, 2005 2032 (38) 1.00 1.00
Risks for HIV
Drug useb 260 (47) 1.84 (1.52—2.23) 1.68 (1.38—2.04)
Sex with CSW 594 (45) 1.71 (1.48—1.97) 1.49 (1.28—1.74)
STD, past or current 1089 (33) 1.04 (0.92—1.17) 1.06 (0.94—1.20)
Blood transfusion history 166 (38) 1.26 (1.02—1.56) 1.16 (0.93—1.44)
Pregnancy 16 (7) 0.17 (0.10—0.28) 0.23 (0.14—0.39)
Unknown 1118 (43) 1.58 (1.40—1.78) 1.50 (1.33—1.71)
Other 71 (47) 1.85 (1.33—2.58) 1.78 (1.27—2.50)
No risk factors 667 (32) 1.00 1.00
CI, confidence interval; CSW, commercial sex worker; STD, sexually transmitted disease.
a Adjusted odds ratios are adjusted for all other variables shown in the table.
b Drug use includes cocaine and injection drug use.Factors associated with increased mortality
Multivariate analysis revealed that after simultaneous
adjustment for age at first diagnosis, gender, calendar date
of diagnosis, number of symptom complexes or opportunistic
diseases associated with HIV, and risk factors for HIV, the
initial stage of presentation was strongly associated with
mortality. Persons diagnosed earlier in the course of disease
(asymptomatic HIV and symptomatic HIV) had a lower hazardFigure 1 Survival of HIV-infected persons in Jamaica by initial
stage at time of report to HIV/AIDS tracking system (HATS)
database.of death (0.32 and 0.49) compared to persons first identified
with AIDS. Age, a greater number of opportunistic diseases
and symptom complexes, and date of diagnosis were also
strongly associated with increased mortality (Table 1).
Factors associated with later presentation to
care
After adjusting for gender, calendar date of diagnosis, num-
ber of opportunistic diseases at the time of diagnosis, initial
stage of presentation, and risk factors for HIV, persons over
age 40 were identified later in the course of disease com-
pared to those in younger age groups (Table 2). History of
drug use, sex with a commercial sex worker, and unknown
risk factors were also associated with later presentation to
care.
Prevalence of symptom complexes and
opportunistic diseases at diagnosis
Males had a significantly higher overall prevalence of symp-
tom complexes or opportunistic diseases than females
(Figure 2). The most prevalent symptom complexes observed
were wasting with weight loss greater than 10% of body
weight (39%), chronic cough greater than 1 month (30%),
oral candidiasis (26%), and shortness of breath (25%).
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Figure 2 Overall prevalence of symptom complexes and opportunistic diseases in the HIV/AIDS tracking system (HATS) database,
stratified by gender. SOB, shortness of breath; Lymph, lymphadenopathy; Gen Derm, generalized dermatitis; CNS, central nervous
system involvement; PNA, pneumonia; Pulm TB, pulmonary tuberculosis. The ‘other’ category includes esophageal candidiasis, oral
hairy leukoplakia, fungal infections, and HIV-related malignancies.Discussion
We analyzed Jamaican HIV/AIDS surveillance data for the
period from 1993 to 2005 to understand trends in survival and
presentation to care in the pre-ARTera in Jamaica. We found
that over one-third of HIV-infected persons in Jamaica were
identified late (with an AIDS diagnosis) and that overall
progression to AIDS was 5.7/100 PY. This rate of progression
was higher in symptomatic persons than in asymptomatic
persons. Mortality rates were also higher in symptomatic
persons than in asymptomatic persons, which is consistent
with data from other countries.8 One- and five-year survival
rates were 97% and 85% for asymptomatic persons, 91% and
72% for persons with symptomatic HIV, and 56% and 40% for
those with AIDS.
The distribution of stage of disease at the time of pre-
sentation is consistent with prior work in Jamaica by Vickers
et al., with most persons presenting with asymptomatic HIV.7
The spectrum of morbidities that we describe is also con-
sistent with the limited literature on HIV disease in Jamaica,
with the most common symptom complexes and opportunis-
tic diseases including HIV wasting, cough, oral candidiasis,
and shortness of breath.7 While lymphadenopathy was the
most common presentation in the study by Vickers et al.,
wasting and cough were themost prevalent symptoms seen in
the HATS dataset. Complete data are still lacking concerning
the etiology of common clinical presentations of HIV disease
and the relative frequency of opportunistic diseases in the
Caribbean region. Aside from the work done in Jamaica,
there are few reports of HIV/AIDS outcomes in the Caribbean
region, with the best data available from Barbados and Haiti.
Morbidity at presentation in a clinical cohort from Barbados
showed that the most commonly seen HIV-related diseases at
presentation in those presenting with symptomatic HIV were
‘other’ diseases, followed by oral candidiasis and generalized
lymphadenopathy.9 The most common cause of death in the
Barbados cohort was opportunistic infections, a result that
supports our finding of higher mortality rates in symptomatic
persons. Though there are numerous reports on HIV-related
morbidity and mortality from Haiti, the spectrum of disease
there differs from that seen in the English-speaking Carib-
bean.10—12 Deschamps et al. reported tuberculosis to be themost common HIV-related illness at presentation in Haiti,
followed by chronic diarrhea and prurigo.11 Comparisons with
specific morbidities that have been reported in other
resource-limited countries, including Coˆte d’Ivoire, Uganda,
South Africa, and India, are difficult, since the HATS dataset
described a combination of clinically observed symptom
complexes and diagnosed opportunistic diseases.8,13—15 How-
ever, the most common opportunistic disease described in
the HATS was oral candidiasis, which is consistent with data
from other countries.15 Whether the cough and shortness of
breath reported in the HATS reflect cases of Pneumocystis
jirovecii pneumonia, as in other settings, cannot be fully
determined because of incomplete data on microbiologic
diagnoses.
Factors associated with later presentation to care
included older age, history of drug use, sex with a commer-
cial sex worker, and unknown risks. While studies in other
Caribbean countries have not reported the predictors of later
presentation to care, the importance of timely presentation
for HIV care is widely recognized, and reports on timing of
presentation for care have been made from Barbados and
Haiti.16,17 Kumar et al. reported that nearly three-quarters of
a clinical cohort in Barbados was diagnosed with HIV infection
for the first time during terminal hospitalization.16 Ivers et al.
reported encouraging results from Haiti, with persons pre-
senting to a rural primary care clinic with a median CD4 cell
count of 321/ml and an overall low rate of missed opportu-
nities for HIV diagnosis observed.17 While the current study is
the first to report specific predictors of later presentation for
care in the Caribbean, these predictors have been examined
in developed settings. In two studies from Australia, older
age was consistently a predictor of later presentation to
care, as was seen in the HATS.18,19 The other predictors of
later presentation to care reported in the studies from
Australia, as well as those reported in one study from the
USA, were different than those seen in Jamaica, which may
be due to different person characteristics in the populations
studied.18—20 These discrepancies highlight the importance
of these setting-specific results from Jamaica for the plan-
ning of national HIV/AIDS policy and response.
Overall mortality in this study was lower than in other
resource-limited countries.8,11,21 In Barbados, an overall
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reported, a rate that is not directly comparable to our results
as the authors did not report person follow-up time.16 In a
report from a longitudinal cohort study in Haiti, investigators
found amedian time to AIDS of 5.2 years and amedian time to
death of 7.4 years, estimates substantially shorter than we
found in the current analysis from Jamaica (greater than 50%
of those with asymptomatic HIV and those with symptomatic
HIV remained AIDS-free at the end of the follow-up period in
the current analysis).11 A review of the natural history of HIV
disease in Africa found mortality rates ranging from 9.3/100
PY to 15.7/100 PY in different African settings.21 In an
additional cohort in West Africa, overall mortality was
reported as 19.8/100 PY, more than twice the rate observed
in the HATS.8 A possible explanation for these discrepancies,
in addition to the differing spectrum of disease between
settings, is the difference in data type; a greater percentage
of persons may be lost to follow-up in a surveillance dataset
compared to a longitudinal cohort, leading to an underre-
porting of death in the surveillance data.22,23 Significant
predictors of mortality included age, date of diagnosis,
number of opportunistic diseases and symptom complexes
associated with HIV, and initial stage of presentation. These
findings are consistent with other studies from Asia and Africa
where age, gender, and stage of disease have all been found
to be predictors of mortality.24—28 There have been no pre-
viously published studies on predictors of mortality in the
Caribbean.
The incidence and prevalence of HIV in Jamaica have been
reported;3 however, no studies to date have documented HIV-
related survival, and the factors associated with worse sur-
vival and later case identification. This is the first study to
utilize the HATS database to assess survival and to identify
factors influencing survival in HIV-infected persons in
Jamaica prior to the introduction of wide access to ART
through the national program. The presentation of persons
with multiple symptom complexes and with a clinical diag-
nosis of AIDS suggests the need for better screening programs
in the region to help identify HIV-infected persons earlier in
the course of disease; a preliminary report on HIV testing in
Jamaica reported only 38% of sexually experienced persons
had had an HIV test.29 Further, there are reports of high levels
of stigma towards HIV-infected persons in Jamaica, which
may deter individuals from seeking HIV testing.30 Of the risk
behaviors reported, ‘unknown’ risk behavior was the greatest
predictor of mortality and late presentation. This emphasizes
the need for better reporting mechanisms of risk behaviors
within this population. History of drug use and sex with a
commercial sex worker were also found to be predictors of
later presentation to care and indicate the need for better
targeting of prevention and screening programs to these
high-risk populations in Jamaica who may be less likely to
access HIV testing and care until they are symptomatic or
have developed AIDS.
There are several limitations to this study. Although the
HATS dataset is the only dataset in Jamaica with data on
HIV-related morbidity and mortality, there is substantial
loss to follow-up in the dataset, which may lead to under-
estimation of mortality, particularly over time.22 Further-
more, staging of disease was done as asymptomatic HIV,
symptomatic HIV, and AIDS for surveillance purposes, and
not by WHO staging criteria, which were designed to mea-sure clinical progression. The dataset also lacks CD4 cell
count measurements because they were not available in
Jamaica during the period of data collection that is exam-
ined in this study.
In summary, these data show a trend of late case identi-
fication of HIV-infected individuals in Jamaica. This study
demonstrates the value of collecting and analyzing national
surveillance data, even those without specific clinical mar-
kers such as CD4 cell counts, for guiding the development of
national prevention and treatment programs. Further, the
collected data may be used as a benchmark to measure the
success of HIV treatment programs. This model can and
should be applied to other settings to identify areas in which
interventions are most required in each setting. In Jamaica,
the data highlight the need for earlier HIV diagnosis and
stronger efforts to scale up antiretroviral treatment pro-
grams.
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